The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

Findings reveal macrophages' role in immune modulation through bacterial metabolites, paving the way for improved therapies ...

A recent study has shed new light on the role of fibro-adipogenic progenitors (FAPs) in muscle regeneration, fibrosis, and degeneration.

Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...

TNF Pharma begins phase 2b clinical trial to evaluate oral TNF-alpha inhibitor drug candidate isomyosamine: Baltimore Thursday, February 27, 2025, 18:00 Hrs [IST] TNF Pharmaceutic ...

Fully funded multi-center study initiated at University of Florida to further explore efficacy of isomyosamine for preventing progressive muscle loss and ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...

Kiniksa has interacted with the U.S. Food and Drug Administration (FDA) and expects to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected ...

6 Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an ...

today announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha (TNF-α) inhibitor drug candidate isomyosamine as a treatment for chronic inflammation associated ...